Home

Articles from Avanzanite Bioscience B.V.

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland.
By Avanzanite Bioscience B.V. · Via Business Wire · June 9, 2025
Avanzanite Bioscience Appoints Sotiris Botozis as General Manager Southern Europe
Avanzanite Bioscience B.V. proudly announces the appointment of Sotiris Botozis as General Manager Southern Europe. As the fourth executive leadership hire of 2025, this move further strengthens Avanzanite’s “Champions League”, highlighting the Company’s commitment to assembling a world-class team.
By Avanzanite Bioscience B.V. · Via Business Wire · April 10, 2025
Avanzanite Bioscience Appoints Chief Financial Officer
Avanzanite Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company advancing life-changing medicines for rare disease patients across Europe, announces today the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO). This milestone appointment further strengthens the company’s leadership team and management board as Avanzanite continues its expansion in Europe and prepares for an exciting future of strategic growth and new partnerships.
By Avanzanite Bioscience B.V. · Via Business Wire · February 3, 2025
Avanzanite Bioscience Announces Appointment of Chief Technical Officer to Accelerate European Expansion and Drive Growth
Avanzanite Bioscience B.V., a leading commercial-stage specialty pharmaceutical company committed to bringing ground-breaking medicines for rare diseases to market, announced today the appointment of Jason Cameron as Chief Technical Officer (CTO). This move marks a significant step in Avanzanite’s mission to accelerate growth, expand its presence in Europe, and advance the company’s next phase of international partnerships and product launches.
By Avanzanite Bioscience B.V. · Via Business Wire · January 13, 2025
Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®
Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company, focused on bringing novel medicines for rare diseases to market, announced today that the European Commission (EC) granted marketing authorisation of AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. The formal approval by the EC follows previously reported positive opinion of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) as well as subsequent positive recommendation of the EMA Committee for Orphan Medicinal Products (COMP). Following more than 16 years of research & development (R&D), AKANTIOR is the first and only authorised medicinal product for the treatment of AK globally.
By Avanzanite Bioscience B.V. · Via Business Wire · August 27, 2024
Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a commercial-stage specialty pharmaceutical company, solely focused on medicines for rare diseases, announced today that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending Marketing Authorisation of AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis (“AK”) in adults and children from 12 years of age.
By Avanzanite Bioscience B.V. · Via Business Wire · June 3, 2024
Avanzanite Bioscience Further Strengthens Leadership Team With Country Manager of Germany
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty commercial-stage pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced the appointment of Marc-Andre Goldschmidt as Country Manager of Germany.
By Avanzanite Bioscience B.V. · Via Business Wire · September 19, 2023
Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal® For the Treatment of Rare Kidney Disease in Germany, Austria, Switzerland and Greece
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators, announced today that it has signed an exclusive distribution agreement with Paris-based specialty pharmaceutical company Advicenne for a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis (dRTA).
By Avanzanite Bioscience B.V. · Via Business Wire · February 28, 2023